Chronic Hepatitis B
Screenings for hepatitis B antigen predict treatment response to lamivudine
Published in Hepatitis Weekly, April 11th, 2005
According to a report from South Korea, "the aim of this study was to determine whether the changing patterns of quantitative hepatitis B e antigen (HBeAg) levels by serial monitoring could predict HBeAg seroconversion and viral breakthrough during lamivudine therapy. We retrospectively analyzed 340 HBeAg positive naive chronic hepatitis B patients treated with lamivudine. The mean duration of lamivudine therapy was 18.7 (range 6-56) months."
"The changing patterns and reduction rates of pretreatment HBeAg levels by serial monitoring were categorized into three groups:...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-04-11)
More Articles from Hepatitis Weekly
- Cancer Therapy
Cancer patients with viral hepatitis benefit from hepatic artery chemotherapy - Hepatitis B Prevention
Hepatitis B vaccine does not stop viral recurrence after liver transplantation - Hepatitis B Therapy
Interferon triggers anti-inflammatory activity in chronic hepatitis B patients - Oncology
Genes predispose breast cancer patients to tamoxifen-induced fatty liver - Virology
Several factors drive the effect of donor age on liver transplant outcomes - Adverse Drug Reaction
Alemtuzumab immunotherapy reactivates hepatitis B virus infection - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
